You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

398 Results
Document
Apr 2019
Guidelines and Advice
Status: Current
Mar 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
iMAtinib,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Document
May 2019
Document
May 2019
Document
May 2019
Document
May 2019
Document
May 2019
Guidelines and Advice
Status: Current
ID: PET 2018-2
Jul 2019
Blog post
In any given year, one in five Canadians will suffer from a mental health problem. For people living with cancer and their families, the risk is...
Aug 2019
Document
Sep 2019

Pages